JP2003507342A5 - - Google Patents

Download PDF

Info

Publication number
JP2003507342A5
JP2003507342A5 JP2001516570A JP2001516570A JP2003507342A5 JP 2003507342 A5 JP2003507342 A5 JP 2003507342A5 JP 2001516570 A JP2001516570 A JP 2001516570A JP 2001516570 A JP2001516570 A JP 2001516570A JP 2003507342 A5 JP2003507342 A5 JP 2003507342A5
Authority
JP
Japan
Prior art keywords
carbon atoms
alkyl
carbon
phenyl
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001516570A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003507342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/021021 external-priority patent/WO2001012227A1/en
Publication of JP2003507342A publication Critical patent/JP2003507342A/ja
Publication of JP2003507342A5 publication Critical patent/JP2003507342A5/ja
Pending legal-status Critical Current

Links

JP2001516570A 1999-08-12 2000-08-02 結腸ポリープおよび直腸結腸癌の処置または抑制のためのｎｓａｉｄおよびｅｇｆｒキナーゼインヒビターを含有する組成物 Pending JP2003507342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
US09/373,261 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (2)

Publication Number Publication Date
JP2003507342A JP2003507342A (ja) 2003-02-25
JP2003507342A5 true JP2003507342A5 (enExample) 2007-09-13

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001516570A Pending JP2003507342A (ja) 1999-08-12 2000-08-02 結腸ポリープおよび直腸結腸癌の処置または抑制のためのｎｓａｉｄおよびｅｇｆｒキナーゼインヒビターを含有する組成物

Country Status (24)

Country Link
EP (1) EP1202746B1 (enExample)
JP (1) JP2003507342A (enExample)
KR (1) KR20020018201A (enExample)
CN (1) CN1229142C (enExample)
AR (1) AR029763A1 (enExample)
AT (1) ATE341341T1 (enExample)
AU (1) AU783116B2 (enExample)
BR (1) BR0013219A (enExample)
CA (1) CA2380904C (enExample)
CZ (1) CZ2002474A3 (enExample)
DE (1) DE60031127T2 (enExample)
DK (1) DK1202746T3 (enExample)
EA (1) EA006876B1 (enExample)
ES (1) ES2272305T3 (enExample)
HK (1) HK1042244A1 (enExample)
HU (1) HUP0203162A3 (enExample)
IL (1) IL147913A0 (enExample)
MX (1) MXPA02001448A (enExample)
NO (1) NO20020663L (enExample)
NZ (1) NZ517120A (enExample)
PL (1) PL353267A1 (enExample)
PT (1) PT1202746E (enExample)
WO (1) WO2001012227A1 (enExample)
ZA (1) ZA200201156B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
NZ521117A (en) * 2000-03-13 2005-02-25 Wyeth Corp Method of treating or inhibiting colonic polyps
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
US6706699B2 (en) 2001-06-21 2004-03-16 Ariad Pharmaceuticals, Inc. Quinolines and uses thereof
ATE341545T1 (de) 2001-07-16 2006-10-15 Astrazeneca Ab Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
ES2295428T3 (es) * 2001-10-25 2008-04-16 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de ciclooxigenasa-2.
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1542989B1 (en) 2002-07-31 2007-04-18 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
AU2003273675A1 (en) 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
DE602005014964D1 (de) 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
NZ550796A (en) 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
JP2011520970A (ja) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
PL387312A1 (pl) * 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
JP2012524119A (ja) 2009-04-20 2012-10-11 オーエスアイ・ファーマシューティカルズ，エルエルシー Ｃ−ピラジン−メチルアミンの調製
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
AU2012262014B2 (en) * 2011-06-01 2016-07-14 Janus Biotherapeutics, Inc. Novel immune system modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391872B1 (en) * 1997-11-04 2002-05-21 Pfizer Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
KR20010031813A (ko) * 1997-11-06 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 결장 폴립 치료용 티로신 키나제 억제제로서의 퀴나졸린유도체의 용도

Similar Documents

Publication Publication Date Title
JP2003507342A5 (enExample)
JP2008515913A5 (enExample)
RU2001131356A (ru) Замещенные 3-циано-[1.7], [1.5] и [1.8] нафтиридиновые ингибиторы тирозинкиназ
EP1202746B1 (en) Nsaid and egfr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
JP2001515071A5 (enExample)
RU2002117422A (ru) 4-пиримидинил-N-ацил-L-фенилаланины
CA3093851A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
RU2006106267A (ru) Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака
RU2004110725A (ru) Гетероциклические производные арилзамещенных пиридинов, использование их в качестве блокаторов натриевых каналов, фармацевтическая композиция
JP2005501796A5 (enExample)
JP2019507179A5 (enExample)
RU2003114740A (ru) Азотсодержащие ароматические производные
RU2008138649A (ru) Применение а1-агонистов аденозина и/или двойных а1/а2в-агонистов аденозина для получения лекарственных средств для лечения заболеваний
RU2004119414A (ru) 3-цианохинолины в качестве ингибиторов egf-r и her2 киназ
JP2001512103A5 (enExample)
EP1796727A2 (en) Method for the treatment of polycystic kidney disease
RU2012147511A (ru) Применение ингибиторов c-src в комбинации с пиримидиламинобензамидом для лечения лейкоза
RU2003103780A (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
US8440675B2 (en) Potentiator of radiation therapy
RU2005103618A (ru) Ингибирующие циклооксигеназу-2 (цог-2) производные пиридина
JP2005503435A5 (enExample)
RU2001135802A (ru) Антагонисты рецептора брадикинина
US20110230499A1 (en) Hsp90 inhibitors for therapeutic treatment
AR053357A1 (es) Uso de un inhibidor de quinasa del receptor del factor de crecimiento epidermico (efgr) en pacientes resistentes a gefitinib
WO2007116029A2 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor